🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07136675
Enrolling by invitation Observational

Healthy Adult Reference Biobank for Cardiovascular Biomarkers in China

NCT07136675 · tracked via the Priya Life Science China tracker
Sponsor
China National Center for Cardiovascular Diseases
Phase
Observational
Started
2025-04-22
Last updated
2025-08-22

Condition(s) studied

Healthy Individuals (Controls)

Study summary

Establishing reference intervals for high-sensitivity cardiac troponin in the apparently healthy population in China.

Eligibility

Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion criteria: Apparent healthy Chinese individuals, aged between 20 and 80 years; Normal electrocardiogram (ECG) during physical examination; Signed informed consent form. Exclusion criteria: Musculoskeletal disease or a history of rheumatoid arthritis, or high-intensity exercise (e.g., marathon) within the past week; Biotin treatment within the past week; Hospitalization for an emergency within the past three months; Pregnancy or lactation within the past year; Diabetes: fasting blood glucose ≥ 7.0 mmol/L; glycated hemoglobin (HbA1c) ≥ 6.5%; Chronic kidney disease: estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m²; Latent heart disease: NT-proBNP \> 125 ng/L or BNP \> 35 ng/L; Known cardiovascular or heart disease in the past: treated with medication or other interventions; Chronic diseases that may affect the heart (cancer/tumor, autoimmune diseases); Hemolysis, lipemia, or insufficient residual sample volume for testing.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, Chinese Academy of Medical Sciences Beijing Beijing Municipality

More China National Center for Cardiovascular Diseases trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07136675 on ClinicalTrials.gov ↗ ← All trials in China